Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00871455 · ClinicalTrials.gov registry record · NA
Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study
A NA study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT00871455 is a NA study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 20 participants.
The verdict
NCT00871455, a NA study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
Insulin-like growth factor I (IGF-I) is used as a measure of the body's ability to produce growth hormone. Growth hormone is important for muscle tissue as well as many other tissues in the body. Growth hormone (GH) and IGF-I have been shown to be reduced in many persons with SCI. Baclofen is a FDA approved drug that is used to treat spasticity. Persons receiving long-term baclofen therapy have been demonstrated to have increased growth hormone and IGF-I levels. IGF-I levels will be determined before and after treatment with baclofen. In this study, the investigators will determine the minimum dose of baclofen at which improvements in GH and IGF-1 levels occur.
Interventions
- DRUG Baclofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-04 |
| Est. Completion | 2011-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00871455
The ClinicalTrials.gov registry entry for NCT00871455 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Baclofen is the first listed.
NCT00871455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00871455 about?
NCT00871455 is a clinical study titled "Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study". Insulin-like growth factor I (IGF-I) is used as a measure of the body's ability to produce growth hormone. Growth hormone is important for muscle tissue as well as many other tissues in the body. Growth hormone (GH) and IGF-I have been shown to be reduced in many persons with SCI. Baclofen is a FDA ...
What is the current status of trial NCT00871455?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2003-04. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00871455?
The interventions under investigation include: Baclofen (DRUG).
Who is sponsoring clinical trial NCT00871455?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.